Sugammadex and Neostigmine Dose-Finding Study for Reversal of Residual Neuromuscular Block at a Train-of-Four Ratio of 0.2 (SUNDRO20)

(Abstracted from Br J Anaesth, 116(2):233–240, 2016) The authors undertook this study to evaluate the dose-response relationship of sugammadex and neostigmine to reverse a commonly observed residual rocuronium-induced neuromuscular block from a train-of-four ratio (TOFR) of 0.2 or greater to a TOFR of 0.9 or greater. Primary outcome measures were the doses required to achieve this effect in 50% of patients within 2 minutes or in 95% of patients within 5 minutes, whereas secondary outcome measures were the doses required for a less advanced acceleration, that is, in 50%of patients within 5 minutes or in 95% of patients within 10 minutes.